Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway

  • Authors:
    • Tadeusz Issat
    • Marek Jakóbisiak
    • Jakub Golab
  • View Affiliations

  • Published online on: December 1, 2006     https://doi.org/10.3892/or.16.6.1273
  • Pages: 1273-1276
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The aim of this study was to investigate the role of the mevalonate pathway in the cytostatic/cytotoxic effects of berberine, a natural plant alkaloid that reduces cholesterol concentration. Berberine as well as lovastatin, an inhibitor of the mevalonate pathway, exerted dose-dependent cytostatic/cytotoxic effects against human breast cancer cells (MDA-MB231). Although the mevalonate pathway metabolites (mevalonic acid, farnesyl pyrophosphate, geranylgeranyl pyrophosphate) effectively reversed cytostatic/cytotoxic effects of lovastatin against MDA-MB231 cells, they were not effective in influencing the cytostatic/cytotoxic effects of berberine. The cytostatic/cytotoxic effects of berberine do not seem to result from inhibition of the mevalonate pathway.

Related Articles

Journal Cover

December 2006
Volume 16 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Issat, T., Jakóbisiak, M., & Golab, J. (2006). Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway. Oncology Reports, 16, 1273-1276. https://doi.org/10.3892/or.16.6.1273
MLA
Issat, T., Jakóbisiak, M., Golab, J."Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway". Oncology Reports 16.6 (2006): 1273-1276.
Chicago
Issat, T., Jakóbisiak, M., Golab, J."Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway". Oncology Reports 16, no. 6 (2006): 1273-1276. https://doi.org/10.3892/or.16.6.1273